Paderborn, 31.01.2022 - Four 20 Pharma GmbH remains on course for internationalization and has successfully entered the British market. The first products have already been delivered to the new partner, the London-based LYPHE GROUP. LYPHE is the leading provider of clinical telemedicine in the UK and has its own distribution system. This gives patients access to treatment with cannabinoid-containing preparations, which are dispensed in the company's own facilities such as "The Medical Cannabis Clinics" and "Dispensary Green".
This partnership ensures that LYPHE and Four 20 Pharma are making new unirradiated medical cannabis preparations available to the UK market, expanding treatment options for patient:ins across the UK.
"We at Four 20 Pharma are very proud to have successfully entered the UK market with our unirradiated products. We have chosen LYPHE GROUP as our strategic partner to provide patient:in with high quality and 100% natural medical cannabis. LYPHE GROUP is one of the pioneers of medical cannabis in the UK. We have been observing this development since the beginning of our market analysis and have convinced our new partner of our "All Natural" approach," said Torsten Greif, CSO of Four 20 Pharma GmbH.
"We are delighted about the partnership with Four 20 Pharma. Without a doubt, the high quality of the non-irradiated products in combination with the "All Natural" approach will be well received by patients. We are giving patients access to new products and I am confident that Four 20 Pharma's products will be a success in the UK," says CCO LYPHE GROUP Chris Ashton.
At least one more EU country will follow in the near future and will be supplied with Four 20 Pharma products. Before entering a new market, Four 20 Pharma GmbH carries out a detailed analysis to identify the potential of new markets. Issues such as regulatory standards, existing distribution channels, size of the target group and other factors play an essential role in the decision-making process.
About Four 20 Pharma GmbH
Four 20 Pharma GmbH is GDP and GMP certified as a manufacturer, wholesaler and importer of medical cannabis and medical devices. The company, based in Paderborn, Germany, was founded in 2018 and holds a narcotics license in accordance with Section 3 of the German Narcotics Act (BtMG) and a pharmaceutical wholesale license in accordance with Section 52a of the German Medicines Act (AMG) for the whole of Europe. In addition, the medical cannabis specialist holds the necessary import licenses for the importation of medical cannabis into Germany, a manufacturing permit, and the necessary, product-specific permit in accordance with § 7 AMG and § 1 AMRadV for the marketing of medicinal products. Four 20 Pharma GmbH is committed to the Association for Cannabis as Medicine (ACM) as a gold sponsor. The company supports physicians, pharmacies, medical institutions and patients as a reliable partner in the field of medical cannabis. For more information, please visit our website at www.420pharma.de.